STEPAN COMPANY (SCL) capitalization

Current snapshot

Market Cap
$1.14B
22.7M shares × $49.98 · as of last filing 2026-03-31
Net Worth
$1.19B
Stockholders' equity · 2026-03-31
Enterprise Value
$1.71B
Market cap + debt − cash
Net Debt
$572.3M
Debt $713.1M − Cash $140.8M

Annual history

One row per fiscal year (10-K). Market cap uses split-adjusted closing price on the fiscal-year-end date × shares outstanding.

Period End Market Cap
FY'25 2025-12-31 $1.08B
FY'24 2024-12-31 $1.48B
FY'23 2023-12-31 $2.17B
FY'22 2022-12-31 $2.46B
FY'21 2021-12-31 $2.89B
FY'20 2020-12-31 $2.77B
FY'19 2019-12-31 $2.39B
FY'18 2018-12-31 $1.73B
FY'17 2017-12-31 $1.85B
FY'16 2016-12-31 $1.88B
FY'15 2015-12-31 $1.14B
FY'14 2014-12-31 $918.5M
FY'13 2013-12-31 $1.50B
FY'12 2012-12-31 $1.26B
FY'11 2011-12-31 $1.80B
FY'11 2010-12-31 $1.69B
FY'11 2009-12-31 $699.7M

Quarterly history

One row per quarter (10-Q and Q4 from 10-K). Market cap uses split-adjusted closing price on the quarter-end date × shares outstanding.

Period End Market Cap
Q1'26 2026-03-31 $1.14B
Q4'25 2025-12-31 $1.07B
Q3'25 2025-09-30 $1.09B
Q2'25 2025-06-30 $1.25B
Q1'25 2025-03-31 $1.26B
Q4'24 2024-12-31 $1.46B
Q3'24 2024-09-30 $1.77B
Q2'24 2024-06-30 $1.93B
Q1'24 2024-03-31 $2.07B
Q4'23 2023-12-31 $2.12B
Q3'23 2023-09-30 $1.72B
Q2'23 2023-06-30 $2.19B
Q1'23 2023-03-31 $2.37B
Q4'22 2022-12-31 $2.37B
Q3'22 2022-09-30 $2.16B
Q2'22 2022-06-30 $2.34B
Q1'22 2022-03-31 $2.29B
Q4'21 2021-12-31 $2.79B
Q3'21 2021-09-30 $2.62B
Q2'21 2021-06-30 $2.81B
Q1'21 2021-03-31 $2.97B
Q4'20 2020-12-31 $2.68B
Q3'20 2020-09-30 $2.53B
Q2'20 2020-06-30 $2.25B
Q1'20 2020-03-31 $2.06B
Q4'19 2019-12-31 $2.31B
Q3'19 2019-09-30 $2.26B
Q2'19 2019-06-30 $2.14B
Q1'19 2019-03-31 $2.04B
Q4'18 2018-12-31 $1.67B
Q3'18 2018-09-30 $2.03B
Q2'18 2018-06-30 $1.82B
Q1'18 2018-03-31 $1.95B
Q4'17 2017-12-31 $1.78B
Q3'17 2017-09-30 $1.96B
Q2'17 2017-06-30 $2.04B
Q1'17 2017-03-31 $1.84B
Q4'16 2016-12-31 $1.83B
Q3'16 2016-09-30 $1.68B
Q2'16 2016-06-30 $1.37B
Q1'16 2016-03-31 $1.27B
Q4'15 2015-12-31 $1.11B
Q3'15 2015-09-30 $950.9M
Q2'15 2015-06-30 $1.24B
Q1'15 2015-03-31 $951.0M
Q4'14 2014-12-31 $892.0M
Q3'14 2014-09-30 $1.02B
Q2'14 2014-06-30 $1.21B
Q1'14 2014-03-31 $1.48B
Q4'13 2013-12-31 $1.47B
Q3'13 2013-09-30 $1.32B
Q2'13 2013-06-30 $1.27B
Q1'13 2013-03-31 $1.44B
Q4'12 2012-12-31 $1.22B
Q3'12 2012-09-30 $2.19B
Q2'12 2012-06-30 $1.07B
Q1'12 2012-03-31 $1.99B
Q4'11 2011-12-31 $822.9M
Q3'11 2011-09-30 $755.6M
Q2'11 2011-06-30 $792.5M
Q1'12 2011-03-31 $809.8M
Q4'11 2010-12-31 $1.69B
Q3'11 2010-09-30 $656.7M
Q2'11 2010-06-30 $760.8M

Methodology

Every figure on this page traces back to SEC EDGAR XBRL company-facts filings (SCL CIK 0000094049), tagged with the us-gaap and dei taxonomies. Filing-anchored figures are rendered server-side: the market cap and enterprise value tiles use the split-adjusted close on the latest reported period-end × shares outstanding, so they reconcile with the equity / debt / cash figures from that same filing. The two price-anchored tiles (market cap + enterprise value) re-anchor on the most recent daily close in the browser when JavaScript is enabled; shares outstanding and debt / cash stay filing-anchored, so the EV bridge still uses the latest statement of financial position. Historical share prices come from our total-returns daily history (split-adjusted); historical market caps are calibrated against today's share count to correct for SEC retroactive split restatements.

For the exact XBRL concepts and formulas, see the methodology reference for net worth, debt, cash, market cap, enterprise value, net debt, shares outstanding, and the historical-market-cap calibration.

Related tickers

CLDX

Celldex Therapeutics, Inc.

LKQ

LKQ CORPORATION

SYRE

SPYRE THERAPEUTICS, INC.